[1]刘包欣子,张 烨,张晶焱,等.健运清化方联合XELOX方案治疗晚期胃癌脾气虚弱证临床研究[J].陕西中医,2023,(10):1377-1381,1386.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.009]
　LIU Baoxinzi,ZHANG Ye,ZHANG Jingyan,et al.Jianyun Qinghua formula and XELOX regimen for the treatment of spleen weakness syndrome in advanced gastric cancer[J].,2023,(10):1377-1381,1386.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.009]
点击复制

健运清化方联合XELOX方案治疗晚期胃癌脾气虚弱证临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年10期
页码:
1377-1381,1386
栏目:
临床研究
出版日期:
2023-10-05

文章信息/Info

Title:
Jianyun Qinghua formula and XELOX regimen for the treatment of spleen weakness syndrome in advanced gastric cancer
作者:
刘包欣子; 张 烨; 张晶焱; 凌博凡; 金志超
(南京中医药大学附属医院 江苏省中医院肿瘤科,江苏 南京210029)
Author(s):
LIU Baoxinzi; ZHANG Ye; ZHANG Jingyan; LING Bofan; JIN Zhichao
(Oncology Department,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)
关键词:
晚期胃癌;  健运清化方;  脾气虚弱证;  不良反应;  平均红细胞血红蛋白量;  血清白蛋白
Keywords:
Advanced gastric cancer;  Jianyun Qinghua formula;  Syndrome of weak temper;  Toxic side effects;  Mean corpuscular hemoglobin;  Human serum albumin
分类号:
R 735.2
DOI:
DOI:10.3969/j.issn.1000-7369.2023.10.009
文献标志码:
A
摘要:
目的:研究探讨健运清化方联合奥沙利铂加卡培他滨(XELOX)方案治疗晚期胃癌脾气虚弱证的近期疗效,总结其应用价值。方法:选取90例晚期胃癌脾气虚弱证的患者,依照随机抽取法平均分组,各45例,对照组采用XELOX化疗方案治疗,观察组在XELOX方案上联合健运清化方治疗,治疗4个月,比较治疗前后两组的中医症候积分、视觉模拟评分法(VAS)评分、血常规、肿瘤标志物及免疫指标的变化; 并观察化疗期内的不良反应; 治疗后的临床疗效和疾病控制率; 随访1年,观察病死率。结果:两组治疗后各项中医症候积分和总积分均明显降低(P<0.05),观察组下降更显著(P<0.05)。观察组治疗后VAS评分显著低于治疗前,且低于对照组(P<0.05)。观察组治疗后血浆中游离血红蛋白(MCH)含量、血清中白蛋白(HSA)、总蛋白(TP)含量均明显高于对照组(P<0.05)。两组治疗后各项肿瘤标志物均明显降低,观察组下降更显著(P<0.05)。经Z检验,观察组化疗期间各项药物不良反应总发生率均显著低于对照组(P<0.05)。观察组治疗后CD3+、CD4+、CD8+、CD4+/CD8+明显升高,均显著高于对照组(P<0.05)。观察组治疗4个月后的疾病控制率显著高于对照组(P<0.05); 观察组随访1年生存率68.9%,显著高于对照组的42.2%(P<0.05)。结论:健运清化方联合XELOX方案治疗晚期胃癌脾气虚弱证的近期疗效,明显优于单纯化疗,可有助缓解临床症状,减轻疾病疼痛,维持和调节机体营养、免疫状态,控制和降低复发、转移概率,提高近期生存率。
Abstract:
Objective:Study and explore the short-term efficacy of Jianyun Qinghua formula combined with oxaliplatin and capecitabine(XELOX)regimen in the treatment of advanced gastric cancer with spleen qi weakness syndrome,and summarize its application value.Methods:A total of 90 patients with spleen qi weakness syndrome of advanced gastric cancer were selected and randomly divided into two groups,with 45 cases in each group.The control group was treated with XELOX chemotherapy regimen,while the observation group was treated with Jianyun Qinghua formula for 4 months.The changes in traditional Chinese medicine syndrome scores,VAS scores,blood routine,tumor markers,and immune indicators of the two groups were compared before and after treatment,and observe the adverse reactions during the chemotherapy period.The efficacy efficiency and disease control rate after treatment; follow up for one year and observe the mortality rate.Results:After treatment,the scores of various symptoms and total scores in both groups were significantly reduced(P<0.05),while the observed group showed a more significant decrease(P<0.05).The VAS score of the observation group after treatment was significantly lower than before treatment,and lower than that of the control group(P<0.05).After treatment,the levels of MCH,HSA,and TP in the blood of the observation group were significantly higher than those of the control group(P<0.05).After treatment,all tumor markers in both groups were significantly reduced(P<0.05),and the observed group showed a more significant decrease(P<0.05).By Z test,the total incidence of adverse drug reactions during chemotherapy in the observation group was significantly lower than that in the control group(P<0.05).After treatment,the levels of CD3+,CD4+,CD8+,CD4+/CD8+in the observation group were significantly higher than those in the control group(P<0.05).The total disease control rate of the observation group after 4 months of treatment were significantly higher than that in the control group(P<0.05).The 1-year survival rate of 68.9% in the observation group was significantly higher than the control group(P<0.05).Conclusion:The short-term efficacy of the combination of Jianyun Qinghua formula and XELOX regimen in the treatment of advanced gastric cancer with spleen qi weakness syndrome is significantly better than that of simple chemotherapy.It can help alleviate clinical symptoms,reduce disease pain,maintain and regulate the body's nutritional and immune status,control and reduce recurrence and metastasis,and improve short-term survival rate.

参考文献/References:

[1] 左婷婷,郑荣寿,曾红梅,等.中国胃癌流行病学现状[J].中国肿瘤临床,2017,44(8):52-58.
[2] 蒋 峰,柳小芳,高艺文,等.解毒散结方联合化疗治疗晚期胃癌疗效及对患者血管内皮生长因子和受体的影响[J].陕西中医,2021,42(5):582-585.
[3] 国家卫生健康委员会.胃癌诊疗规范(2018年版)[J].中华消化病与影像杂志,2019,9(3):118-144.
[4] 王德禄.中医内科学[M].北京:中国中医药出版社,2006:407-424.
[5] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:233-237.
[6] 孙 兵,车晓明.视觉模拟评分法(VAS)[J].中华神经外科杂志,2012,28(6):645.
[7] Trotti A,Colevas AD,Setser A,et al.CTCAE v3.0:Development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
[8] Eisenhauer EA,Therasse P,Bogaerts J,et al.Newresponse evaluation criteria in solid tumours:Revised RECIST guide line(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[9] 孙凯旋,张眉佳,廖成功,等.中国人群胃癌发病影响因素的Meta分析[J].现代肿瘤医学,2022,30(8):1431-1438.
[10] 徐 慧,秦静静,张 曹,等.血浆D-二聚体水平与胃癌患者预后关系Meta分析[J].陕西医学杂志,2022,51(9):1158-1162.
[11] 郭 栋,魏 鹏,梁 刚,等.原纤维蛋白1在胃癌组织中的表达及与预后的关系[J].陕西医学杂志,2021,50(4):499-502.
[12] 张莲兴,杨 燕,张秋宁,等.益气健脾方辅助SOX化疗对晚期胃癌患者T淋巴细胞亚群平衡及胃肠激素的影响[J].中国老年学杂志,2021,41(21):4638-4641.
[13] 唐继云,李东芳.从健脾论治胃癌研究进展[J].中医药导报,2015,21(6):72-75.
[14] 许 萍,许 雯,计 强,等.健脾为基础的中药复方治疗晚期胃癌的研究进展[J].湖北中医杂志,2019,41(9):63-66.
[15] 宋成鑫,葛信国,储 晶.养阴健脾散毒法辅助化疗治疗晚期胃癌临床研究[J].陕西中医,2020,41(11):1543-1547.
[16] 李力恒,陈丽萍,胡晓阳,等.柴胡的化学成分及药理作用研究进展[J].中医药学报,2023,51(2):109-112.
[17] 侯 莹,严 波.补中益气汤联合xelox方案对晚期胃癌近期疗效和远期生存率的影响[J].世界中医药,2020,15(3):426-429.
[18] 胡 玥,吴存恩,邵 杰,等.益气健脾解毒方治疗中晚期胃癌疗效及对免疫功能和不良反应的影响[J].现代中西医结合杂志,2022,31(24):3463-3467.
[19] 王冬慧,郭 芳,郭 玮,等.参芪扶正注射液结合XELOX化疗方案对晚期胃癌肿瘤标志物的影响[J].中华中医药学刊,2021,39(12):225-228.
[20] 张维霞,苏 萍,赵爱军.白术的炮制方法及其药理作用研究进展[J].中医药导报,2022,28(5):110-115.
[21] 倪建成,范永飞,叶祖云.太子参化学成分、药理作用和应用的研究进展[J].中草药,2023,54(6):1963-1977.
[22] 李 瑞,王 宇.黄芪多糖的抗肿瘤作用机制研究进展[J].西部中医药,2022,35(9):150-154.
[23] 毕天琛,杨国宁,马海春.中药薏苡仁化学成分及药理活性研究进展[J].海峡药学,2019,31(11):52-56.
[24] 刘豪杰,陈雪蕾,包萨如拉.白花蛇舌草-半枝莲药对乙酸乙酯组分对胃癌SGC-7901细胞周期的影响[J].中医学报,2022,37(10):2198-2204.

相似文献/References:

[1]李 雯 ,杜雅冰△,冯 堃,等.养正消积胶囊联合心理干预治疗胃癌晚期疗效及对患者生活质量、情绪的影响*[J].陕西中医,2019,(6):722.
　LI Wen,DU Yabing,FENG Wei,et al.Study on effects quality of life and emotion of Yangzheng Xiaoji capsule combined with psychological intervention on advanced gastric cancer[J].,2019,(10):722.
[2]蒋 峰,柳小芳,高艺文,等.解毒散结方联合化疗治疗晚期胃癌疗效及对患者血管内皮生长因子和受体的影响[J].陕西中医,2021,(5):582.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.009]
　JIANG Feng,LIU Xiaofang,GAO Yiwen,et al.Effect of Jiedu Sanjie recipe combined with chemotherapy on patients with advanced gastric cancer and the effect of serum VEGF and VEGFR-1[J].,2021,(10):582.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.009]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81904110)
更新日期/Last Update: 2023-10-09